|
|
 | | | |
- close
- close
- close
- close
Suggest other news sources for this topic
WIKI ANALYSIS|
Error creating thumbnail: convert: unable to open image `/home/wikinvest/src_live_1/mediawiki/images/c/ce/IPO.jpg': No such file or directory @ blob.c/OpenBlob/2480. convert: missing an image filename `/home/wikinvest/src_live_1/mediawiki/images/thumb/c/ce/IPO.jpg/40px-IPO.jpg' @ convert.c/ConvertImageCommand/2800. |
This company completed an initial public offering (IPO) of its stock in 2010. View articles that reference this company. Recent IPOs: Globe Specialty Metals • LogMeIn • Invesco Mortgage Capital • Medidata • Chemspec |
Tengion (TNGN) (NASDAQ:TNGN) is a pharmaceutical company developing functional neo-organs using a patient's own cells. Neo-organs are replacement organs. The lead product candidate is the Neo-Urinary Conduit. This product is a catalyst that regenerates urinary bladder tissue, targeting bladder cancer patients who had their bladder removed. On 10 March 2010, the company commenced Phase I trials on bladder cancer patient. [1]
The company also has the product candidate Neo-Bladder Augment for the treatment of neurogenic bladder. This is a dysfunctional bladder due to some neurological disease. This product is in Phase II. There is a large market for treatments of bladder cancer. According to the National Cancer Institute, bladder cancer is the sixth most common cancer with 10,000 cases each year requiring bladder removal. [1]
The company's initial public offering of stock filed on the NASDAQ and went public on 08 April 2010. The stock was priced at $5.00, below the IPO range of $8.00-$10.00. The company raised $30 million by selling 6 million shares. [1]
This company is a pre-revenue and is developing its product to enter the market soon.
References
| |||||||
